361 related articles for article (PubMed ID: 22153602)
1. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
2. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Banz K; Bischoff H; Brunner M; Chouaid C; de Castro Carpeño J; de Marinis F; Grossi F; Vergnenègre A; Walzer S
Lung Cancer; 2011 Dec; 74(3):529-34. PubMed ID: 21592611
[TBL] [Abstract][Full Text] [Related]
3. Cost-minimisation analysis of erlotinib in the second-line treatment of non-small-cell lung cancer: a Brazilian perspective.
Doral Stefani S; Giorgio Saggia M; Vicino dos Santos EA
J Med Econ; 2008; 11(3):383-96. PubMed ID: 19450094
[TBL] [Abstract][Full Text] [Related]
4. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
Carlson JJ; Wong WB; Veenstra DL; Reyes C
J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.
Zeng X; Peng L; Li J; Chen G; Tan C; Wang S; Wan X; Ouyang L; Zhao Z
Clin Ther; 2013 Jan; 35(1):54-65. PubMed ID: 23328269
[TBL] [Abstract][Full Text] [Related]
7. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting.
Nadler E; Forsyth M; Satram-Hoang S; Reyes C
J Thorac Oncol; 2012 Jan; 7(1):212-8. PubMed ID: 22124474
[TBL] [Abstract][Full Text] [Related]
8. Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.
Karampeazis A; Voutsina A; Souglakos J; Kentepozidis N; Giassas S; Christofillakis C; Kotsakis A; Papakotoulas P; Rapti A; Agelidou M; Agelaki S; Vamvakas L; Samonis G; Mavroudis D; Georgoulias V
Cancer; 2013 Aug; 119(15):2754-64. PubMed ID: 23661337
[TBL] [Abstract][Full Text] [Related]
9. Comment and reply on: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective.
Arellano J; Leteneux C
J Med Econ; 2008; 11(2):363-66; author reply 366-70. PubMed ID: 19450092
[No Abstract] [Full Text] [Related]
10. Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: a real-world cost-effectiveness analysis.
Cromwell I; van der Hoek K; Malfair Taylor SC; Melosky B; Peacock S
Lung Cancer; 2012 Jun; 76(3):472-7. PubMed ID: 22226627
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study.
Vergnenegre A; Corre R; Berard H; Paillotin D; Dujon C; Robinet G; Crequit J; Bota S; Thomas P; Chouaid C;
J Thorac Oncol; 2011 Jan; 6(1):161-8. PubMed ID: 21150465
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of pemetrexed plus cisplatin as first-line therapy for advanced nonsquamous non-small cell lung cancer.
Klein R; Muehlenbein C; Liepa AM; Babineaux S; Wielage R; Schwartzberg L
J Thorac Oncol; 2009 Nov; 4(11):1404-14. PubMed ID: 19786904
[TBL] [Abstract][Full Text] [Related]
13. Erlotinib versus pemetrexed for pretreated non-squamous non-small cell lung cancer patients in clinical practice.
Zugazagoitia J; Puente J; González-Larriba JL; Manzano A; Sotelo M; Hernández S; Sanz J; Pérez P; Díaz-Rubio E
Oncology; 2013; 84(5):255-64. PubMed ID: 23428780
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.
Matter-Walstra K; Joerger M; Kühnel U; Szucs T; Pestalozzi B; Schwenkglenks M
Value Health; 2012 Jan; 15(1):65-71. PubMed ID: 22264973
[TBL] [Abstract][Full Text] [Related]
15. Araújo A, et al. An economic analysis of erlotinib, docetaxel, pemetrexed and best supportive care as second or third line treatment of non-small cell lung cancer. Rev Port Pneumol 2008; 14(6):803-827.
Bartminski W
Rev Port Pneumol; 2009; 15(3):555-9; author reply 560-6. PubMed ID: 19526635
[No Abstract] [Full Text] [Related]
16. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer.
Bradbury PA; Tu D; Seymour L; Isogai PK; Zhu L; Ng R; Mittmann N; Tsao MS; Evans WK; Shepherd FA; Leighl NB;
J Natl Cancer Inst; 2010 Mar; 102(5):298-306. PubMed ID: 20160168
[TBL] [Abstract][Full Text] [Related]
17. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).
Carlson JJ; Reyes C; Oestreicher N; Lubeck D; Ramsey SD; Veenstra DL
Lung Cancer; 2008 Sep; 61(3):405-15. PubMed ID: 18295368
[TBL] [Abstract][Full Text] [Related]
18. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Karayama M; Inui N; Kuroishi S; Yokomura K; Toyoshima M; Shirai T; Masuda M; Yamada T; Yasuda K; Suda T; Chida K
Cancer Chemother Pharmacol; 2013 Aug; 72(2):445-52. PubMed ID: 23807323
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
20. Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Guirgis HM
J Oncol Pract; 2012 Jul; 8(4):224-30. PubMed ID: 23180986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
